Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Diagnostic Biomarkers Market In 2029?
The scale of the diagnostic biomarkers market has seen substantial expansion in the previous few years. This market is expected to inflate from $65.25 billion in 2024 to $75.46 billion in 2025, marking an impressive compound annual growth rate (CAGR) of 15.7%. Factors contributing to this growth during the historic period include an increase in chronic disease cases, advancements in omics technologies, a higher demand for personalized medicine, improved awareness about early detection of diseases, and a rise in non-invasive diagnosis strategies.
In the coming years, it’s predicted that the diagnostic biomarkers market will witness substantial growth, expanding to a value of $135.36 billion in 2029 with a compound annual growth rate of 15.7%. Various factors will contribute to this expected growth during the projected period, such as the rising adoption of liquid biopsy techniques, escalating investment in the research of biomarkers, growing emphasis on precision medicine, and enlarged application scope within the field of neurodegenerative diseases. Forecasted period trends involve advancements in both machine learning and artificial intelligence, the merging of multi-omics methods, the creation of point-of-care diagnostic instruments, a shift towards digital biomarkers, increased utilization of wearable health monitoring gadgets, and a heightened focus on the validation and standardization of biomarkers.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp
What Are the Core Market Drivers Propelling Growth in the Diagnostic Biomarkers Industry?
The upward trend in the incidence of cancer propels the expansion of the diagnostic biomarkers market. Contributing factors to the rise in cancer cases include an aging demographic, changes in lifestyle, exposure to environmental hazards, and advancements in diagnostic techniques. Diagnostic biomarkers are critical in the fight against cancer as they aid in early detection, precision diagnosis, and the creation of individualized treatment plans, thereby enhancing patient results. To illustrate, data from the American Cancer Society, a US-based non-profit cancer advocacy group, showed that in January 2024, cancer case numbers had risen to 2,001,140, a 2.19% increase from 1,958,310 cases in 2023. The escalating frequency of cancer diagnosis contributes to the continued expansion of the diagnostic biomarkers market.
How Is the Diagnostic Biomarkers Market Segmented?
The diagnostic biomarkersmarket covered in this report is segmented –
1) By Product: Safety Biomarkers; Efficacy Biomarkers; Validation Biomarkers
2) By Application: Oncology; Metabolic Disease; Neurological Disease
3) By End User: Hospitals; Cancer Research Institutes; Diagnostic Labs
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers; Organ-Specific Safety Biomarkers; Drug-Induced Injury Biomarkers
2) By Efficacy Biomarkers: Predictive Biomarkers; Prognostic Biomarkers; Pharmacodynamic Biomarkers
3) By Validation Biomarkers: Genomic Biomarkers; Proteomic Biomarkers; Metabolomic Biomarkers
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21171&type=smp
Which Regions Are Driving the Next Phase of the Diagnostic Biomarkers Market Growth?
North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Diagnostic Biomarkers Market?
Leading companies in the diagnostic biomarkers market are prioritizing the advancement of non-invasive testing procedures, such as blood-based biomarker tests, in an effort to provide both convenience and personalized treatment plans for patients. Blood-based biomarker tests, which analyze precise biological markers in the blood, create an opportunity for less invasive detection and monitoring of diseases, such as Alzheimer’s. For example, Quanterix Corporation, a life sciences company based in the US, introduced LucentAD, a blood-based biomarker test, in July 2023. This test is aimed at supporting healthcare professionals in identifying Alzheimer’s disease in patients exhibiting initial cognitive symptoms. LucentAD measures plasma levels of p-Tau 181, a specific type of phosphorylated tau protein and biomarker linked to amyloid pathology in the brain, which is a distinguishing feature of Alzheimer’s. The core purpose of LucentAD is to provide a more accessible and less intrusive diagnosis method than traditional ones, such as cerebrospinal fluid analysis or amyloid positron emission tomography, thus simplifying the examination process for potential Alzheimer’s patients.
View the full report here:
https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report
How Is the Diagnostic Biomarkers Market Defined and What Are Its Core Parameters?
A diagnostic biomarker is a biological measure that assists in the diagnosis of a disease, helping to differentiate it from other conditions. It can encompass various findings, including laboratory results, radiological images, genetic markers, and physiological changes, and may also provide insights into disease progression and treatment efficacy.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21171
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model